Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?Accesswire • 06/30/23
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse MembersGlobeNewsWire • 06/26/23
Agile Therapeutics Announces the Availability of Twirla® through FPA Women's HealthGlobeNewsWire • 06/15/23
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®GlobeNewsWire • 06/13/23
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate UpdateGlobeNewsWire • 05/11/23
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023GlobeNewsWire • 05/08/23
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 04/26/23
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/22/23
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023GlobeNewsWire • 03/21/23
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementGlobeNewsWire • 02/27/23
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline EvaluationGlobeNewsWire • 02/01/23
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common StockGlobeNewsWire • 01/26/23
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial PlanGlobeNewsWire • 01/09/23
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth ConferenceGlobeNewsWire • 12/01/22
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/22
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022GlobeNewsWire • 10/26/22